{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036706","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.332766+00:00","generated_at":"2026-06-08T22:45:01.825327+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prime Medicine reports Q3 net loss of $50.7M, cash runway through end 2024; provides pipeline updates","bullets":["R&D expenses $41.0M (up 64% YoY); G&A $10.5M (up 59%); net loss widened to $50.7M from $29.4M.","Cash, equivalents, and investments $178.8M as of Sept 30, 2023, down from $307.4M at Dec 31, 2022.","FDA granted Rare Pediatric Drug designation for PM359 (CGD); IND-enabling studies started, IND filing planned for 2024.","Preclinical data showed up to 50% liver editing in NHPs for GSD1b and up to 70% correction in photoreceptors for retinitis pigmentosa.","U.S. PTO issued third patent covering Prime Editing systems with PEgRNA, Prime Editor protein, and optionally a recombinase."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036706","json":"https://secwatch.observer/filing/0001628280-23-036706.json","markdown":"https://secwatch.observer/filing/0001628280-23-036706.md","text":"https://secwatch.observer/filing/0001628280-23-036706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/0001628280-23-036706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/prme-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:45:01.825327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"962f3ad588e47ac0059c5acf2c5efaedb68ab095","claim":"Prime Medicine, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 3, 2023, Prime Medicine, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/0001628280-23-036706-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}